Primary Isolated Bone Marrow Diffuse Large B-cell Lymphoma with Hemolytic Anemia as the First Manifestation

Ja Young Lee, M.D.1, Jae Hyun Kim, M.D.1, Jeong Hwan Shin, M.D.1, Hye Ran Kim, M.D.1, Jeong Nyoe Lee, M.D.1, Ki Hyang Kim, M.D.2, Won Sik Lee, M.D.2, Young Don Joo, M.D.2, Chang Hak Sohn, M.D.2 and Chan-Hwan Kim, M.D.3

Departments of 1Laboratory Medicine, 2Hemato-oncology and 3Pathology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea

Primary isolated bone marrow disease as a presenting feature of diffuse large B-cell lymphoma is very rare. We describe the first Korean case of isolated bone marrow diffuse large B-cell lymphoma with hemolytic anemia as the first manifestation. A 32-year-old man was admitted to our hospital presenting with fever and hematuria. He had severe anemia and high lactate dehydrogenase activity. His peripheral blood smear and laboratory findings were suggestive of intravascular hemolytic anemia. The bone marrow biopsy revealed involvement with diffuse large B-cell lymphoma. A computed tomographic scan showed splenomegaly, but no lymphadenopathy. Our case shared some clinical features with the Asian variant of intravascular B-cell lymphoma, but there was infrequent involvement of the sinusoids of lymphoma cells and no hemophagocytosis. Our patient was treated with R-CHOP regimen for six cycles and he is in remission after autologous peripheral blood stem cell transplantation. (Korean J Hematol 2008; 43:48-52.)

Key Words: Diffuse large B-cell lymphoma, Bone marrow, Hemolytic anemia

INTRODUCTION

The most frequent type of non-Hodgkin's lymphoma (NHL) is diffuse large B-cell lymphoma (DLBL). Patients may present with nodal or extranodal disease. Extranodal involvement is mostly considered as stage IV, and portends a poorer prognosis. The most common extranodal site is the gastrointestinal tract, but virtually any location has been reported as a primary site. Although bone marrow (BM) involvement in DLBL is relatively infrequent at presentation and is generally believed to represent systemic dissemination of disease, some cases may arise primarily in BM.1-6) Primary BM involvement in NHL may be more frequent in cases of T-cell lymphoma, as only eight cases in 32 previous reports were DLBL in English literature.3,5,6) But primary isolated BM DLBL was not reported in Korea.

We describe a patient with primary isolated bone marrow DLBL (IBMDLBL) who presented with hemolytic anemia as the first manifestation. Hemolytic anemia is a relatively common complication in patients with NHL; however, there have been only one report of autoimmune hemolytic anemia.
anemia (AIHA) in association with IBMDLBL. This is the first case of IBMDLBL with hemolytic anemia as the first manifestation.

**CASE REPORT**

A 32-year-old man was hospitalized with hematuria and a febrile sensation for 2 weeks. Physical examination revealed hepatosplenomegaly but no overt lymphadenopathy. No specific previous medical history and family history were observed. He had no medication history up to recently. Laboratory studies revealed a hemoglobin level 3.8g/dL, a hematocrit 12.4%, a white blood cell count 5.4×10⁹/L with 54% granulocytes, 37% lymphocytes, 9% monocytes, a platelet count 254×10⁹/L, and reticulocytes 7.4%. Erythrocyte sedimentation rate was 24mm/hr. Total protein was 5.7g/dL, albumin 3.0g/dL, total bilirubin 2.0mg/dL, AST/ALT 44/28U/L and Lactate dehydrogenase (LDH) 728IU/L (reference range, 232∼410 IU/L). The blood urea nitrogen was elevated (24mg/dL), however the levels of serum creatinine and electrolytes were normal. On urinalysis, urobilinogen and hemosiderin were positive, urine myoglobin was negative. Serum haptoglobin was 220.8mg/dL (reference range, 30∼200mg/dL) and C reactive protein was 8.11mg/dL. An extensive work-up for hemolytic anemia including direct/indirect Coombs' test, autohemolysis test, acidified serum lysis test, and sucrose hemolysis test were all negative except the osmotic fragility test, which was slightly increased. A peripheral blood smear showed moderate anisopoikilocytosis with spherocytosis, polychromasia, and nucleated red blood cells (4/100 WBCs). Thus it was suggestive of intravascular hemolytic anemia although haptoglobin was not decreased.

Repeated blood and urinary cultures were negative. Tests for viruses including HCV, HBs, CMV, and HIV were negative. The results of serologic testing for Epstein-Barr virus were consistent with past infection. Antinuclear antibodies and rheumatoid factor were negative or normal. Initial broad-spectrum antibiotics with third generation cephalosporin and aminoglycosides and blood transfusions were administered. Hemoglobin level was elevated to 8.0g/dL, however high fever continued and a platelet count dropped to 88×10⁹/L.

Thus BM aspiration and biopsy were performed. The specimen was markedly hypercellular (80∼90%) and diffusely infiltrated by atypical large lymphoid cells with round nuclear contours and scanty cytoplasm (Fig. 1). Immunohistochemical studies revealed that the neoplastic

**Fig. 1.** Histologic features of diffuse large B cell lymphoma in the bone marrow. (A) Atypical large lymphoma cells are diffusely infiltrated (H&E stain, original magnification ×200). (B) Higher power view shows a diffuse lymphoid infiltrate with typical morphologic features of diffuse large B-cell lymphoma (H&E stain, original magnification ×400).
cells were positive for CD20 and CD45 and negative for TdT, CD45RO, CD3, CD43, CD5, and CD79a (Fig. 2). The morphologic features, together with the immunohistochemical results, were consistent with diffuse large B-cell lymphoma. A whole-body staging computed tomography (CT) scan showed no nodal involvement except a mild enlarged spleen. The whole-body bone scan was normal. On $^{18}$F-fluorodeoxyglucose positron emission tomography, BM hyperplasia was observed.

Primary isolated BMDLBL was diagnosed, and the patient was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab for six cycles. After the first chemotherapy, fever and hematuria were subsided and the laboratory finding of the patient was promptly normalized except neutropenia because of BM depression. After 2 months, the BM specimen was negative for lymphoma cells, and he subsequently received an autologous peripheral blood stem cell (PBSC) transplantation. At present, he is in remission.

**DISCUSSION**

Non-Hodgkin’s lymphoma restricted to the BM is extremely rare, with only 32 fully documented cases in the English-language literature, of which 8 were IBMDLBL. These patients consisted of four men and four women with an age range from 42 to 86 years. The most frequent clinical findings were weakness, fatigue, and B symptoms of NHL according to the Ann Arbor staging system. Most patients had neither hepatosplenomegaly nor lymphadenopathy. Only one patient had hepatosplenomegaly. Six patients had bicytopenia or pancytopenia and elevated serum LDH. Peripheral blood smears in five patients showed a leukoerythroblastic reaction.

Our patient also presented fever and general weakness. He had mild hepatosplenomegaly and the similar laboratory findings in previous cases of IBMDLBL. But his complaint of hematuria is unusual. He had severely decreased hemoglobin (3.8g/dL). Laboratory findings, including a peripheral blood smear were compatible with the diagnosis of intravascular hemolytic anemia except elevated haptoglobin. Serum haptoglobin level was generally decreased or absent in hemolytic anemia. But our patient presented with sustained high fever and elevated CRP at diagnosis of hemolytic anemia, it presumed that he had acute inflammation and haptoglobin was elevated as an acute phase reactant.

Hemolytic anemia was rarely found in previous cases of IBMDLBL and only one case was reported about IBMDLBL complicated with AIHA.
in Japan. Hemolytic anemia is often among the clinical manifestations of intravascular B-cell lymphoma (IVL). This rare type of large-cell lymphoma is associated with hematologic abnormalities, including autoimmune hemolytic anemia, pancytopenia, and disseminated intravascular coagulation. It is well known that IVL often involves the nervous system, the skin, or both but rarely the BM, lymph nodes, liver, or spleen. Our patient did not have skin lesions or neurologic signs, and his BM did not demonstrate intravascular infiltration of lymphoma cells. So this case is different from typical IVL observed in Western countries but rather is similar to Japanese cases recently reported by Murase and Nakamura and called the Asian variant of IVL (AIVL). To determine whether AIVL was present, we reassessed the BM aspirate and biopsy but found neither hemophagocytosis nor sinusoidal involvement with neoplastic large B cells, making the diagnosis of AIVL strongly indicated from a clinical viewpoint. This case met all three clinical and laboratory criteria but only one of the three histopathologic criteria. So this case was not confirmed AIVL. It was confirmed to IBMDLBL with hemolytic anemia as the first unusual clinical manifestation. This case demonstrates that hemolytic anemia could be accompanied by the course of IBMDLBL and underlines the importance of BM examination as a diagnostic tool in the lymphoid malignancy combined with the unusual hematologic abnormalities. Various chemotherapeutic protocols were used in the eight patients in previous reports of IBMDLBL. Except for one patient, all patients manifested initial transient improvement or complete remission. Five of them showed a good response to CHOP or CHOP with rituximab, but no standard protocol seems to offer a definitive treatment for IBMDLBL. In our case, the patient was treated with CHOP plus rituximab for six cycles, and subsequent BM examination showed complete remission.

The prognosis of IBMDLBL generally is poor because most patients are older than 60 years, elevated LDH is frequently found, and BM involvement is defined as stage IV disease. Among the previously reported eight patients with IBMDLBL, four died either of complications of chemotherapy or of relapse after treatment. Their survival after diagnosis ranged from 10 days to 17 months. Two younger patients, who were 42 and 45 year olds, survived for more than 4 years, however. One had received BM transplantation, and the other showed complete remission in response to chemotherapy after relapse. Our patient was younger than other patients in previous reports, and his IPI score was 2. He received autologous PBSC transplantation after complete remission in response to treatment with CHOP plus rituximab. At present, he has survived for more than one year.

In conclusion, isolated BM disease in DLBL is rare. Clinical characteristics, therapy, and prognoses are diverse and not well defined. We report a unique case of IBMDLBL with hemolytic anemia as the initial clinical manifestation in Korea and describe details of the clinicopathologic features of IBMDLBL from a review of the related literature.
이식을 받았으며 현재 1년 이상 완전 관해상태를 유지하고 있다.

REFERENCES